Lanciego Carlos, De Miguel Silvia, Padilla Manuel, Perea Miguel, Rodriguez-Merlo Rufo, García-García Lorenzo
Unit of Interventional Radiology, Hospital Virgen de la Salud, Toledo, Spain.
Cardiovasc Intervent Radiol. 2006 Jul-Aug;29(4):586-94. doi: 10.1007/s00270-004-0297-9.
The purpose of this study was to evaluate, in a prospective, single-center study, the effectiveness of Song's polyurethane stents, modified "in-house," in the percutaneous management of epiphora. Patients (n = 170; age range 18-83, mean = 64; 50 male, 120 female) with severe epiphora had the modified stents inserted (183 eyes/195 stents) to treat unilateral/bilateral and complete/partial obstruction of the nasolacrimal system. The etiology of the obstruction was idiopathic in 119 cases (61%) and chronic dacryocystitis in 76 (39%). The set designed by Song was used in all patients but modified by us such that the extreme end is cone-shaped. The original technique was slightly modified by us and the procedure was conducted on an outpatient basis. The initial technical success rate of stent placement was 97%. Resolution of epiphora was complete in 180 eyes and partial in 3. On follow-up (mean = 18 months; range: 2 days to 24 months), 165 of 195 stents (85%) remained patent. Primary patency rates at follow-up were 86%, 84%, 84%, and 79% in the first 6 months, second and third 6 months, and the present (24 months), respectively. Stents became obstructed in 30 patients, but all but 2 were easily withdrawn and 20 of these patients remained asymptomatic for a mean of 14 months (secondary patency of 67%). Following stent removal, the withdrawn stent was replaced with a new stent in the same intervention on 14 occasions. In another six cases, patency was re-established without the need of a second stent. The procedure is simple and safe, both in stent insertion as well as in mechanical de-blocking and withdrawal when occluded. Success was >80 % in the short term (1-year follow-up). Stenting failure does not preclude other treatment because with the modification that we had introduced, the extreme end of the stent becomes more accessible to mechanical de-blocking, withdrawal, and relocation. The levels of primary and secondary patencies are promising and warrant more extensive investigation.
本研究旨在通过一项前瞻性单中心研究,评估经改良的“院内自制”宋氏聚氨酯支架在经皮治疗泪溢中的有效性。170例(年龄范围18 - 83岁,平均64岁;男性50例,女性120例)严重泪溢患者接受了改良支架植入(183只眼/195个支架),以治疗鼻泪系统的单侧/双侧及完全/部分阻塞。阻塞病因中,119例(61%)为特发性,76例(39%)为慢性泪囊炎。所有患者均使用宋氏设计的支架,但我们对其进行了改良,使末端呈锥形。我们对原技术进行了轻微改良,该手术在门诊进行。支架置入的初始技术成功率为97%。180只眼泪溢完全缓解,3只眼部分缓解。随访(平均18个月;范围:2天至24个月)时,195个支架中有165个(85%)保持通畅。随访时前6个月、第二个和第三个6个月以及目前(24个月)的初始通畅率分别为86%、84%、84%和79%。30例患者的支架发生阻塞,但除2例之外均易于取出,其中20例患者平均14个月无症状(二次通畅率为67%)。取出支架后,14例患者在同一次干预中用新支架替换取出的支架。另外6例患者无需置入第二个支架即可重新建立通畅。该手术在支架置入以及阻塞时的机械疏通和取出方面均简单安全。短期(1年随访)成功率>80%。支架置入失败并不排除其他治疗方法,因为通过我们引入的改良,支架末端更易于进行机械疏通、取出和重新定位。初次和二次通畅水平令人满意,值得进行更广泛的研究。